Lifestance Health Group (LFST) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue grew 19% year-over-year to $312.7 million, driven by a 15% increase in visit volumes and a 13% rise in clinician base to 7,269, with net loss narrowing to $6.0 million from $61.6 million in Q3 2023.

• Adjusted EBITDA more than doubled to $30.7 million, reflecting strong operating leverage and margin expansion.

• Center Margin for Q3 was $100.4 million (32.1% of revenue), up 32% year-over-year.

• Cash and cash equivalents at quarter-end were $102.6 million, with net long-term debt of $279 million.

• Digital patient check-in tools and machine learning pilots continued to improve efficiency, satisfaction, and clinician retention.

Financial highlights

• Q3 revenue reached $312.7 million, up 19% year-over-year, with visit volumes at 2.0 million (+15% Y/Y) and total revenue per visit at $158.5.

• Center Margin was $100.4 million (32.1% margin), and Adjusted EBITDA was $30.7 million (9.8% margin), both showing significant year-over-year growth.

• Net loss for Q3 was $6.0 million, a significant improvement from $61.6 million in Q3 2023.

• Free cash flow in Q3 was $17.7 million; cash flow from operations for the nine months was $44.9 million.

• DSO improved by two days sequentially to 47 days.

Outlook and guidance

• Full-year 2024 revenue guidance raised to $1,228–$1,248 million, Center Margin to $382–$398 million, and Adjusted EBITDA to $105–$115 million.

• Q4 2024 guidance: revenue of $302.5–$322.5 million, Center Margin of $89–$105 million, Adjusted EBITDA of $18–$28 million.

• Positive Free Cash Flow expected for the full year, with minimal margin improvement in 2025 due to flat rate growth and increased clinician costs.

• Stock-based compensation expected at or below $80–$95 million, down from $99 million last year.

• Substantially higher De Novo clinic openings planned for 2025; 6 de novo center openings assumed for 2024.